SCHEMBL7101109

SCHEMBL7101109

COC(=O)c1ccc(Cn2c(=O)[nH]c3ccc(C(=O)OCc4ccccc4)cc3c2=O)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.55
HPGD P15428 6/20 0.55
LMNA P02545 2/20 0.55
MAPK10 P53779 1/20 0.55
ALDH1A1 P00352 8/20 0.49
KDM4E B2RXH2 6/20 0.49
KMT2A Q03164 4/20 0.49
GAA P10253 5/20 0.49
HSD17B10 Q99714 3/20 0.49
PKM P14618 2/20 0.49
HTT P42858 2/20 0.49
GLA P06280 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
MEN1 O00255 2/20 0.49
USP2 O75604 1/20 0.48
TSHR P16473 1/20 0.48
CASP1 P29466 1/20 0.48
CASP7 P55210 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
TP53 P04637 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6258325 0.93 ALDH1A1 (0.56) MAPTHPGDLMNAMAPK10ALDH1A1
SCHEMBL6243745 0.92 MAPT (0.60) MAPTHPGDLMNAMAPK10ALDH1A1
SCHEMBL6242637 0.87 ALDH1A1 (0.50) MAPTHPGDLMNAMAPK10ALDH1A1
SCHEMBL6510914 0.84 KDM4E (0.65) MAPTLMNAALDH1A1KDM4EKMT2A
SCHEMBL7194154 0.84 HPGD (0.59) MAPTHPGDLMNAMAPK10ALDH1A1
SCHEMBL7745468 0.84 LMNA (0.70) MAPTHPGDLMNAMAPK10ALDH1A1
SCHEMBL2118623 0.83 ALDH1A1 (0.69) MAPTHPGDLMNAMAPK10ALDH1A1
SCHEMBL27605975 0.82 HPGD (0.52) MAPTHPGDLMNAMAPK10ALDH1A1
SCHEMBL6397114 0.82 MAPT (0.52) MAPTHPGDLMNAMAPK10ALDH1A1
SCHEMBL6217417 0.82 SMN1; SMN2 (0.64) HPGDALDH1A1KDM4EKMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1368324-A1 QUINAZOLINES AS MMP-13 INHIBITORS Warner-Lambert Company LLC (US) 2003-12-10 EP disclosed
US-20020193377-A1 Quinazolines as MMP-13 inhibitors ANDRIANJARA CHARLES (FR) 2002-12-19 US disclosed
WO-2002064572-A1 QUINAZOLINES AS MMP-13 INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193377-A1 Quinazolines as MMP-13 inhibitors MMP13, MMP9, MMP3 MAPT 4823/4885HPGD 228/4885LMNA 3812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.